Prolonged Treatment Interruption after Immunologic Response to Highly Active Antiretroviral Therapy

Tarwater, Patrick M.; Parish, Michelle; Gallant, Joel E.
December 2003
Clinical Infectious Diseases;12/1/2003, Vol. 37 Issue 11, p1541
Academic Journal
Duration of treatment interruption (TI) was investigated in 105 human immunodeficiency virus—infected patients whose antiretroviral therapy was interrupted with the intention to resume therapy on the basis of clinical or laboratory indicators. In a mixed cohort study, 57% of patients had not resumed therapy at the time of writing (median TI duration, 114 weeks); the most recent analysis of this group revealed a mean CD4 cell count of 500 cells/mm³. Patients with lower CD4 cell counts at therapy initiation were more likely to resume therapy than were those with counts of >500 cells/mm³ (<200 cells/mm³ [relative hazard, 4.4]; and 200–350 cells/mm³ [relative hazard, 2.9]). Patients who met current United States Department of Health and Human Services criteria for starting therapy at the time of therapy initiation were 3 times more likely to resume therapy than were those who did not. Our results have implications for this TI strategy: there may be a subset of patients who can safely discontinue therapy for prolonged periods of time.


Related Articles

  • Multi-targeting the Entrance Door to Block HIV-1. Borkow, G.; Lapidot, A. // Current Drug Targets - Infectious Disorders;Mar2005, Vol. 5 Issue 1, p3 

    The multistep nature of HIV-1 entry provides multisite targeting at the entrance door of HIV-1 to cells. Blocking HIV-1 entry to its host cells has clear advantages over blocking subsequent stages in the life cycle of the virus. Indeed, potent cooperative and synergistic inhibition of HIV-1...

  • The Optimal Time to Initiate HIV Therapy Under Ordered Health States. Shechter, Steven M.; Bailey, Matthew D.; Schaefer, Andrew J.; Roberts, Mark S. // Operations Research;Jan/Feb2008, Vol. 56 Issue 1, p20 

    The question of when to initiate HIV treatment is considered the most important question in HIV care today. Benefits of delaying therapy include avoiding the negative side effects and toxicities associated with the drugs, delaying selective pressures that induce the development of resistant...

  • Innate Immunity and Intracellular Trafficking: Insights for Novel Anti- HIV-1 Therapeutics. Jones, Kate L.; Mak, Johnson // Current Pharmacogenomics;Jun2005, Vol. 3 Issue 2, p97 

    It is now evident that host cells have evolved a remarkable variety of antiretroviral activities to defend themselves against viral invaders and in return viruses have developed ingenious ways to circumvent these defences and, in some cases, actually hijack cellular proteins in order to...

  • Host factors and HIV-1 replication: clinical evidence and potential therapeutic approaches. Santa-Marta, Mariana; De Brito, Paula Matos; Godinho-Santos, Ana; Goncalves, Joao // Frontiers in Immunology;Oct2013, Vol. 4, p1 

    HIV and human defense mechanisms have co-evolved to counteract each other. In the process of infection, HIV takes advantage of cellular machinery and blocks the action of the host restriction factors. A small subset of HIV+ individuals control HIV infection and progression to AIDS in the absence...

  • The Quest for an HIV-1 Therapeutic Vaccine. Gandhi, Rajesh Tim; Altfeld, Marcus // Journal of Infectious Diseases;8/15/2005, Vol. 192 Issue 4, p556 

    Focuses on the quest for an HIV-1 therapeutic vaccine. Factors that influenced the decline of the initial peak of viral replication; Functional impairment of the cellular immune response early during the course of infection; Initiation of antiretroviral therapy during acute infection to protect...

  • HTLV-III.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1096 

    An encyclopedia entry for "HTLV-III," which stands for human T-cell lymphotropic virus type III, is presented.

  • human T-cell lymphotropic virus type III.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1097 

    A definition of the medical term "human T-cell lymphotropic virus type III," which refers to the former name for human immunodeficiency virus, is presented.

  • CE/CME questions.  // AIDS Alert;Jan2007, Vol. 22 Issue 1, p12 

    A quiz about human immunodeficiency virus is presented.

  • Sensitization of cells and retroviruses to human serum by... Takeuchi, Yashuhiro; Porter, Colin D. // Nature;1/4/1996, Vol. 379 Issue 6560, p85 

    Reports that mammalian C-type retroviruses are inactivated by human serum following the trigger of the classical complement cascade. Retroviruses human immunodeficiency virus and human T-cell leukemia virus resistant to human complement; Detailed aspects.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics